Posts

Claris collects $118M to take eye drop into pivotal testing next year

Claris Biotherapeutics has raised $118 million in a Series B financing to advance its experimental eye drop, CSB-001, into pivotal testing in 2027 for the blinding corneal disease limbal stem cell deficiency (LSCD). The funds will support late-stage clinical development, including planned pivotal studies in the first half of 2027 involving about 400 LSCD patients, primary efficacy endpoints focused on visual acuity and anatomical measures. Claris will also use the proceeds to advance ongoing proof-of-concept and non-interventional natural history studies in LSCD, as well as pre-commercialization activities, with proof-of-concept data expected in the second half of 2026. Sources: 07-28-2026 Press Releases from Claris Bio An eye drug biotech banks $118M and stocks its executive ... Novo Holdings-backed Claris Bio emerges with $118M Latest News and Press Releases Claris Biotherapeutics' Post Kalaris Reports Full Year 2025 Financial Results and Provides Business Updat...

Altimmune’s Next-Gen GLP-1 Curbs Heavy Drinking in Unequivocal Phase 2 alcohol use disorder win

MannKind Receives FDA Approval for Furoscix ReadyFlow Autoinjector for Edema in Heart Failure and CKD

GSK unveils 3‑year cost‑saving plan to fund late‑stage R&D and move research HQ to Cambridge from AZ”,

FDA's re‑evaluation of Capricor and Replimune drugs underscores that review ≠ reversal

RA Capital Launches Rare Disease Company Oak Hill Bio onto Nasdaq via SPAC

FDA Staff Signal Replimune RP1 Melanoma Trial Failure, Slashing Stock

Apnimed Targets Up to $160M IPO for Sleep Apnea Drug Oxnimbi Launch

Assured Raises $19 Million Series A to Accelerate AI-Driven Provider Credentialing

Kura Reports Durable Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve ccRCC at KCRS 2026

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

MapLight's schizophrenia drug dampens once‑daily hopes despite Phase 2 win

Legend Biotech CEO Ying Huang Resigns